FOR US AUDIENCES ONLY
NASHVILLE, TN –(BUSINESS WIRE)– New diagnostic is less invasive and more convenient compared to standard of care ExEm® Foam Inc announced today that ExEm® Foam ((air polymer-type A) intrauterine foam), the only FDA-approved contrast agent for ultrasound tubal patency testing, is now available at select fertility clinics nationwide. The [...]
NYU Langone Health The ExEm® Foam Inc. team was excited to meet with the renowned Dr. Steven R. Goldstein, M.D. this past week at NYU Langone Health, one of the nation’s premier academic medical centers located in the heart of Manhattan. The goal of the visit was to [...]
Johns Hopkins Medicine The first president of Johns Hopkins University, Daniel Coit Gilman, believed that teaching and research go hand in hand. He presumed that success in one depends on success in the other. He also believed that sharing knowledge and discoveries would help make the world a better [...]
Texas Children's Hospital The ExEm® Foam Inc team visited Texas Children's Hospital to introduce them to the Foam procedure. The hospital prides itself for providing the most advanced fertility treatments to help patients conceive. With ExEm® Foam ((air polymer-type A) intrauterine foam), women with known or suspected infertility can [...]
ExEm Foam Team visits Mayo Clinic Rochester The ExEm® Foam Team was excited to visit the Mayo Clinic Rochester to officially bring the Foam Procedure to the US.The new technology in tubal patency testing in women with know or suspected infertility, offers fertility clinics [...]
ASRM 2019 Scientific Congress Prize Paper Session 1 The first six papers are candidates for the ASRM Scientific Congress Prize Paper Awards. Six additional candidates will be presented during the Prize Paper Candidates’ session on Tuesday.
ExEm® Foam is an innovative, FDA-approved product that offers a less invasive and effective alternative to other tubal patency assessment procedures, like laparoscopy or X-Ray HSG.
ExEm® Foam Inc. is an affiliate of IQ MEDICAL VENTURES, B.V. ExEm® is a registered trademark of GISKIT PHARMA B.V.
Important Safety Information: ExEm® Foam should not be used on patients who are pregnant, have known or suspected lower genital tract inflammation or infection, have had a gynecologic procedure within the last 30 days, have vaginal bleeding, or have known or suspected reproductive tract neoplasia. Common side effects include pelvic and abdominal pain, vasovagal reactions (and associated symptoms such as nausea and faintness), and post-procedure spotting. Click here for full prescribing information.
References:
1. Ludwin I., Ludwin, A. et al. Accuracy of hysterosalpingo-foam sonography in comparison to hysterosalpingo-contrast sonography with air/saline and to laparoscopy with dye. Human Reproduction 2017, 32(4):758–69
2. Riganelli L., Casorelli A. et al. Ultrasonography reappraisal of tubal patency in assisted reproduction technology patients: comparison between 2D and3D-sonohysterosalpingography. A pilot study. Minerva Ginecologica 2018, 70(2):123-28
3. Dreyer, K., Out, R. et al. Hysterosalpingo-foam sonography, a less painful procedure for tubal patency testing during fertility workup compared with (serial) hysterosalpingography: A randomized controlled trial. Fertility and Sterility 2014, 102(3):821-25
ExEm_US_02_v27
ExEm® Foam Inc. is an affiliate of IQ MEDICAL VENTURES, B.V. ExEm® is a registered trademark of GISKIT PHARMA B.V.
